CVS plunges 16% after cutting its guidance and citing 'slowing prescription growth'
Sarah Fortune
"Very recent pharmacy network changes in the marketplace are expected to cause some retail prescriptions to begin migrating out of our pharmacies this quarter," said CEO Larry Merlo in the earnings statement.
"In addition, we are currently experiencing slowing prescription growth in the overall market as well as a soft seasonal business. These factors combined are leading us to reduce the mid-point of our guidance for this year by five cents per share."
In a statement, CVS said it expected full-year adjusted earnings per share between $5.77-$5.83, down from a previously announced range of $5.81-$5.89, and below analysts' estimate for $5.85.
For the third quarter, CBS reported net revenue of $44.6 billion, below the forecast for $45.3 billion according to Bloomberg.
The stock lost 15% this year through the market close on Monday.
Markets Insider
- India is an oasis of growth amid a slower global economic landscape, witnessing a once-in-a-generation growth: G20 Sherpa Amitabh Kant
- Mutual fund stake in NSE-listed cos at all time high; FPIs at 11-yr low
- Gold prices today: Yellow metal climbs Rs 230 while silver jumps Rs 700
- Indegene IPO: Company details to risk factors, all you need to know
- Indegene IPO subscribed 1.67 times on Day 1 of offer